Biologics in Congenital Ichthyosis: Are They Effective?

The discussion centered around the effectiveness of biologics in treating congenital ichthyosis, prompted by observed cytokine alterations and the potential to repurpose existing biologics. A retrospective study involving 98 patients from various countries, primarily with types such as Netherton syndrome and congenital ichthyosis from erythroderma, was conducted to assess the impact of biologics. Results indicated that efficacy varied significantly—with 46% of patients responding positively to treatment, while 54% were non-responders, including some experiencing worsening symptoms. Among responders, improvements in pruritus, erythema, and scaling were noted, and some patients reported secondary benefits like enhanced hair growth and quality of life. However, a substantial proportion withdrew from treatment due to ineffectiveness or side effects, with a notable portion experiencing only transient improvements. Analysis suggested that IL 12/23 and IL 4 inhibitors showed better efficacy compared to IL 17. The findings highlight limitations such as the heterogeneous patient population, treatment regimens, and a lack of robust statistical comparisons due to study design. Despite some positive outcomes, high success rates in published literature likely reflect a publication bias, emphasizing that biologics should be cautiously considered primarily for severe erythrodermic cases. The study calls for more stringent clinical trials to substantiate these findings and better understand the utility of biologics in congenital ichthyosis.